289 related articles for article (PubMed ID: 36259611)
1. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Long M; Mims AS; Li Z
Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
[TBL] [Abstract][Full Text] [Related]
2. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
[TBL] [Abstract][Full Text] [Related]
3. Redirecting T cells to hematological malignancies with bispecific antibodies.
Velasquez MP; Bonifant CL; Gottschalk S
Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
[TBL] [Abstract][Full Text] [Related]
4. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
6. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
[TBL] [Abstract][Full Text] [Related]
7. T Cell-Activating Bispecific Antibodies in Cancer Therapy.
Trabolsi A; Arumov A; Schatz JH
J Immunol; 2019 Aug; 203(3):585-592. PubMed ID: 31332079
[TBL] [Abstract][Full Text] [Related]
8. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
Park JA; Cheung NV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
[TBL] [Abstract][Full Text] [Related]
9. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents.
Jiang X; Chen X; Carpenter TJ; Wang J; Zhou R; Davis HM; Heald DL; Wang W
MAbs; 2018; 10(6):876-889. PubMed ID: 29985776
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
12. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
Demanet C; Brissinck J; De Jonge J; Thielemans K
Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies in haematological malignancies.
Viardot A; Bargou R
Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
[TBL] [Abstract][Full Text] [Related]
16. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
17. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
Front Immunol; 2020; 11():762. PubMed ID: 32457743
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models.
Sandker GGW; Middelburg J; Wilbrink E; Molkenboer-Kuenen J; Aarntzen E; van Hall T; Heskamp S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899133
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic bispecific antibodies against intracellular tumor antigens.
Xu G; Luo Y; Wang H; Wang Y; Liu B; Wei J
Cancer Lett; 2022 Jul; 538():215699. PubMed ID: 35487312
[TBL] [Abstract][Full Text] [Related]
20. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
Hoseini SS; Espinosa-Cotton M; Guo HF; Cheung NV
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
